LEGN (Legend Biotech) Tariff Resilience Score: 4/10 (As of Jul. 02, 2026)


LEGN Legend Biotech Corp LEGN
71 GF Score
Price $29.99
GF Value $99.04
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech Tariff Resilience Score?

Legend Biotech LEGN +0.22% 71 Tariff Resilience Score is 4 as of Jul. 02, 2026. GuruFocus rates LEGN with a GF Score™ of 71/100 and a GF Value™ of $99.04 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,374 Biotechnology companies, Legend Biotech ranks better than 52.33% on this metric.

Legend Biotech has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Legend Biotech has Legend Biotech has significant global operations, with manufacturing in China and sales in the U.S. and Europe. This exposes it to tariff risks, especially in the biotech sector. Mitigation strategies include alternative suppliers and strategic partnerships.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Legend Biotech might have Average Resilient.

Legend Biotech  (NAS:LEGN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Legend Biotech Tariff Resilience Score Related Terms

LEGN vs TVTX, ORKA, CRSP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Legend Biotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Legend Biotech Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Legend Biotech's Tariff Resilience Score falls into.


LEGN
71GF Score
Legend Biotech Corp LEGN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Legend Biotech (LEGN) has a Tariff Resilience Score of 4 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Legend Biotech ranks #655 out of 1374 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Legend Biotech's Tariff Resilience Score too high?
Legend Biotech's current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Legend Biotech's value of 4 is 0% at this industry median. Based on the distribution chart, Legend Biotech ranks #655 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Legend Biotech has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Tariff Resilience Score compare to TVTX and ORKA?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #655 out of 1374 companies for Tariff Resilience Score. This puts Legend Biotech in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Legend Biotech's value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $99.04, compared to a current price of $29.99 — trading 69.7% below its estimated fair value. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Legend Biotech's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Tariff Resilience Score is 4 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $29.99 is trading 69.7% below its estimated GF Value™ of $99.04. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Tariff Resilience Score: 4
  • GF Value™: $99.04 vs. price of $29.99 (69.7% below fair value)
  • GF Score™: 71/100 with 3 warning signs
  • Industry Position: 0% at the Biotechnology median (#655 of 1374)

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
71GF Score

Get the complete analysis for LEGN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.99
Price
$99.04
GF Value